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The development of a physiologically relevant, in vitro microvasculature network 
platform is an important goal across a variety of applications including perfusable tissue 
graft development, physiologically relevant drug screening platforms and the modeling of 
dysfunctional vasculature in disease states such as cancer and diabetes. Vascular network 
development and formation is enhanced through a defined extracellular matrix 
composition, specific combinations of growth factors and flow control in a microfluidic 
device. The objective for the project outlined here is develop a working model of 
vasculogenesis and to further the understanding of how various factors can influence the 
growth and development of a microvasculature network. Here, a three-channel 
microfluidic device was designed and optimized to provide an adequate environment to 
foster vessel development. A range of factors were tuned including ECM composition, 
endothelial cell density, fluid flow control and growth factor conditions. The importance 
of the work presented here is the resulting functional model of a microvasculature 
network that can be implemented in future studies in the Wood Lab to make platforms 
















TABLE OF CONTENTS 
 
LIST OF TABLES..…………………………………………………………………..…...v 
LIST OF FIGURES...…...……………………………………………...………………...vi 
CHAPTER 1 INDRODUCTION TO VASCULOGENESIS……………….................….1 
 Section 1.1 What is Vasculogenesis? ……………………………………………..1 
 Section 1.2 Endothelial Progenitor Cells………………………………………….3 
 Section 1.3 Biomechanical and Cell Specific Inducing Factors ……...…………4 
 Section 1.4 Growth Factors ……………………………………………….….… 6 
 Section 1.5 Vasculogenesis in Disease States……………………………………8 
CHAPETR 2 CURRENT MODELS OF VASCULOGENESIS.………………….........10 
           Section 2.1 Current Vasculogenic Models ……………………………………….10 
           Section 2.2 Microfluidic Devices in Vasculogenic Modeling..……….…….……13 
           Section 2.3 Current Microfluidic Models on Factor Dependent Vasculogenesis ..18 
CHAPTER 3 METHODS.………………………………………..…………..……….....20 
 Section 3.1 Cell Culture and Preparation ……………………………….………20 
 Section 3.2 ECM Gel Fabrication ………………………………………………20  
 Section 3.3 Device Design and Fabrication …………………………………….21 
 Section 3.4 Endothelialization of Media Channels ………………………….….23 
             Section 3.5 Growth Factor Experimental Set Up ……………………..………...23 
             Section 3.6 Imaging and Statistical Analysis……………………………………25 
CHAPTER 4 RESULTS………..……………………………………………………..…26 
 Section 4.1 Optimization of a Microvasculature Network ……………………..26 
     Section 4.1.1 Fibrin Creates an Environment for Vessel Formation ……….26 
       Section 4.1.2  Endothelialization of channels/PDMS slides …………..……30 
 Section 4.2  Investigating the Effects of Growth Factors on a Microvasculature 
N      Ne……Ne…    Network……………….………………..………………………....32 
iv 
 
CHAPETR 5 DISCUSSION…….………………………………………………………36 





























LIST OF TABLES 
 




























LIST OF FIGURES 
 
Figure 1:  a) Endothelial cells create the inner lining of blood vessels, the endothelium 
(Lifeline Cell Technology 2019). b) Endothelial cells self-assemble into microvasculature 
networks (Peak et al., 2015) c) EPCs can become mobilized from bone marrow to the site 
of tissue repair and undergo vasculogenesis. Biorender…………….……………………3 
Figure 2:  A cancerous tumor with proliferative vessel dysregulation and the metastatic 
process of tumor cells. (Biorender)……………………………………………….………9 
Figure 3:  Examples of current vasculogenic models a) Custom chamber for vascular 
constructs to measure gel compaction and interstitial flow on various microvascular 
characteristics most notably vessel alignment and lumen density (Morin et al., 2014).  b) 
Design of a multi tissue spheroid with encapsulated endothelial cells surrounding by a 
tissue environment  (Buno et al., 2016).……………………………..…………………..13 
Figure 4:  Examples of current vascular modeling methods and applications using 
microfluidic platforms a) Endothelial cell lining method in preformed microfluidic 
channels (X. Wang et al., 2018). ( b) (i)Multi-channel microfluidic device design that 
relies on vasculogenesis (ii) Developed, fully perfused microvasculature network. 
(Whister et al., 2012).  c) Vascularized microtissues on a microfluidic model d) 
Microfluidic drug screening and development platform (Hsu et al., 2013) d) Biomimetic 
anti-tumor drug screening platform (Shi et al., 2019). e) Microfluidic device with organ 
specific vasculature for metastatic cancer cell studies. (Arrigoni et al., 2016).………....16 
Figure 5: Design of microfluidic device a) CAD design of the microfluidic device 
platform b) Magnified post design of the microfluidic device with direction of media 
flow through the device  c) Microfluidic device with PDMS device plasma bonded to a 
glass slide with inlet/outlet media channel and gel channel pipet tips d) Anatomical 
model of microfluidic device design (Biorender)…………………..………………..…..22 
Figure 6:  Experimental set up of growth factor experiments. Devices were loaded with 
fibrin and HUVECS. Two experimental branches were set up, with one group receiving 
growth factor solutions right away at day 0 until day 5 and the other group at day 3 until 
day 5. Devices were fed twice at day until they were imaged on day 5. Biorender……..24 
Figure 7: Experimentation with different ECM compositions in a standardized well plate 
a) HUVECs seeded on top of Matrigel at a concentration of 8 million cells/ml  b) 
Matrigel/Collagen combination in a 1:1 ratio with a HUVEC concentration of 9 million 
cells/ml c) Fibrin ECM with HUVECs at a concentration of 9 million cells/ml d) Fibrin 
ECM with HUVECs at a concentration of 9 million cells/ml stained with Calcein and 
DRAQ5 Scale bars = 100um……………………………………...………….………….28 
Figure 8: Microfluidic device assays with 12 million cells/ml a) Collagen/Matrigel ECM 
where cells failed to form vessels b) Fibrin ECM supported the development of a 
vii 
 
microvascular network c) Microvascular network formation in fibrin ECM stained with 
Calcein d) Microvascular network formation in fibrin ECM with media supplemented 
with 50ug/ml of VEGF and stained with Calcein. Scale bars = 100um ………………...29 
Figure 9: a) Control. Glass slide with no fibronectin b) Glass slide with channels perfused 
with media supplemented with 10ug/ml fibronectin c) PDMS coated glass slide with no 
fibronectin d) PDMS coated glass slide with channels perfused with media supplemented 
with 10ug/ml fibronectin. Scale bars = 100um………………………………………………..31 
Figure 10:  Microvascular network development over a control group and four growth 
factor conditions in three different experimental trials. Scale bar = 100um……………..33 
Figure 11: Vessel development compared between two groups 1) Growth factor solutions 
added at Day 0 and 2) at Day 3 for all four growth factor conditions. Scale bar = 100um  
……………………………………………………………………………………………35 
Figure 12: Experiments 1-3 in the immediate application of the growth factor 
combinations on day 0 and in the delayed application of growth factors on day 3 as well 
as the individual performance of growth factors (n= 3) for a) vessel % area b average 
vessel length and c) total vessel length. Graphs are presented as mean + standard 
deviation. ……………………………………………………………….…………..……36 
Figure 13:  Comprehensive analysis of vessel % area, average vessel length and total 
vessel length with a direct comparison between immediate and delayed growth factor 
application compared to a control. (n=9) Graphs are presented as mean + standard 
















 Introduction to Vasculogenesis  
Section 1.1 – What is Vasculogenesis?  
During human embryonic development, the cardiovascular system is the first 
functional organ system to develop (Patel-Hett & D’Amore, 2011). This is vital as every 
other organ system to sequentially develop will completely depend on the functionality of 
the circulatory system as it is a vast, complex network of blood vessels responsible for a 
wide range of functions. Every cell relies on the vasculature to permeate all tissues of the 
body to deliver essential nutrients and carry out vital biological processes they need to 
survive. Blood vessels are necessary to maintain homeostasis in the body through gas 
exchange, cellular and biochemical transport, temperature regulation, nutrient delivery, 
and waste removal (Kim et al., 2013). 
The foundation of this complex system are endothelial cells, the cells that line blood 
vessels in a monolayer forming the endothelium (Fig. 1a) (Tronolone & Jain, 2021). 
Intercellular signaling promotes the growth and development of the endothelial cells into 
mature blood vessels. These cells can expertly adapt to various biochemical and 
biophysical signals from the surrounding microenvironment. For example, 
mechanoreceptors on the endothelial cell surface can sense the shear stress from blood 
flow. The endothelial cells signal this information to the surrounding cells and the blood 
vessel can change its wall thickness and diameter to adapt to blood flow conditions.  
Cells can also rapidly respond to neural signals for vessel dilation or expansion. The 
endothelial cells will release nitric oxide gas to relax smooth muscle cells and dilate the 
vessels (Lewis et al., 2002).  The cardiovascular system is heavily dependent on 
endothelial cells for maintaining homeostasis throughout the body and for growth and 
repair of blood vessels.  
In normal, healthy adult tissues cycles of remodeling and reconstruction often occur 
periodically. Endothelial cells are needed both for the growth of new vessels and the 
repair of existing vessels. Endothelial cells have the capacity to proliferate and migrate to 
these areas of the body by responding to cellular signaling produced by the tissue they are 
being recruited to (Lewis et al., 2002). One of the most important cellular signaling
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mechanisms are the release of growth factors. While the signaling pathway is complex, 
the key part of vessel growth and development depends on vascular endothelial growth 
factor (VEGF). VEGF induces a chemotactic response from the endothelial cells (Patel-
Hett & D’Amore, 2011). Once at the site of tissue repair or growth, endothelial cells can 
proliferate and establish themselves in the tissue through endothelium repair or the 
formation of new vessels. 
This vessel formation and development relies partly on a process called 
vasculogenesis. Vasculogenesis is the self-assembly of individual endothelial cells into 
dynamic, functional microvascular networks. (Fig. 1b). As cells grow and develop, they 
are able to connect to other cells, a process known as anastomosis, to form tubular 
structures in a cobblestone like structure, a vascular plexus (X. Wang et al., 2018). This 
process involves complex and dynamic interactions between the endothelial cells and the 
extracellular matrix (ECM) surrounding the cells. Chemical signals released by 
endothelial cells and physical factors such as ECM density dictate the formation and 
functionality of initial tube formation and the resulting vasculature. Endothelial cell 
behavior is impacted by ECM composition, structure, and mechanical properties. For 
example, the number and size of vessels that form is directly correlated to the density of 
the ECM material such as collagen or fibrin (Little et al., 2000). 
Traditionally vasculogenesis was understood as a process that occurred in only 
embryonic development, crucial in the formation of a functional vascular network. In 
adults, it was thought that angiogenesis was the key process in wound healing and vessel 
growth. Angiogenesis is similar to vasculogenesis as it involves the creation of new blood 
vessels, however it differs in that it encompasses the process of sprouting from an already 
existing parent vessel (Tronolone & Jain, 2021).  However, it has recently been 
discovered that vasculogenesis is a main contributor to tissue repair in adults as well as in 
cases of tissue ischemia (Parham et al., 2014). Tissue ischemia is a common stimulus for 
new vascular growth. Ischemia is defined as the occurrence of a decrease in blood supply 
to tissue. Consequently, oxygen and nutrient supplies are restricted in the affected area. A 
shortage of oxygen causes an increase in the intracellular concentration of hypoxia 
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inducible factor -1 (HIF-1). HIF-1 stimulates the production of VEGF causing an 
increase in VEGF production (Lewis et al., 2002). Nearby tissues respond by recruiting 
and incorporating endothelial cells into new functional vasculature. The recent discovery 
that vasculogenesis plays an important part in wound healing is supported by evidence 
that the local population of endothelial cells used for tissue repair is increased by 
endothelial cells recruited from the blood stream and bone marrow stem cell populations 
(Fig. 1c.) The endothelial cells are derived from bone marrow and are known as 
endothelial progenitor cells (EPCs) (Balaji et al., 2013). 
Section 1.2 – Endothelial Progenitor Cells   
Postnatal vasculogenesis is made possible by EPCs that are present circulating in 
the peripheral circulatory system and residing in the bone marrow. Most EPC populations 
are located in the stem cell portion of bone marrow and maintained in position by potent 
chemoattractants. During homeostatic conditions low numbers of EPCs are present in 
circulation.  When tissue is injured or becomes ischemic, EPCs become mobilized and 
Fig. 1. a) Endothelial cells create the inner lining of blood vessels, the endothelium (Lifeline Cell 
Technology 2019). b) Endothelial cells self-assemble into microvasculature networks (Peak et al., 2015) 
c) EPCs can become mobilized from bone marrow to the site of tissue repair and undergo 
vasculogenesis. (Biorender).  
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are recruited to the tissue repair site directed by physical and chemical signaling (Balaji et 
al., 2013). Hypoxia is the most powerful physical stimuli for vasculogenesis. New vessel 
growth is necessary to restore oxygen delivery to the hypoxic tissue. The occurrence of 
ischemia causes cytokine release, an up-regulation in surface markers and the 
proliferation of mature endothelial cells in damaged tissues.  Hypoxic conditions also 
cause growth factors such as VEGF, basic fibroblast growth factor (bFGF) and other 
chemoattractant signals to be released by cells in the damaged tissues. VEGF is the 
strongest chemoattractant that results from the hypoxic conditions. EPCS are able to 
respond to the increased VEGF signaling because they express strong angiogenic surface 
markers. VEGF signaling overcomes chemoattractant signaling keeping the EPCs in the 
bone marrow, mobilizing EPCs to damaged tissue (Spring et al., 2005). EPCs migrate 
through blood vessels and ECM until they arrive at the site of injury where they are 
activated by tissue specific chemokines. As EPCs differentiate into endothelial cells, they 
adhere to ECM structural components through integrin-mediated adhesion. This adhesion 
is accomplished by fibronectin, a multifunctional adhesive glycoprotein. In wound 
healing, it’s vital for EPCs to be able to adhere to the ECM to effectively repair the 
damaged tissue (Balaji et al., 2013). The EPCs then differentiate into mature endothelial 
cells and undergo vasculogenesis or regulate the assembly of pre-existing endothelial 
cells into vascular networks (Fig. 1c).   
The success of this neovascularization is dependent on the ability of the EPCs to 
respond to molecular cues. EPCs need to be able to interact with bone marrow, peripheral 
blood, blood vessels and the site of tissue injury to be able to successfully remodel the 
damaged tissue and restore proper function.  While this process of EPCs being recruited 
to areas of tissue injury to undergo neovascularization has been observed, the exact 
mechanisms of EPC recruitment and incorporation into new blood vessels in the ischemic 
tissue remain unknown.  
Section 1.3 – Biomechanical and Cell Specific Inducing Factors  
Collagen and fibrin are the most common biomaterials used in vasculogenesis 
assays due to their biological relevance and their tunable mechanical properties. Collagen 
and fibrin are both ECM proteins that act as excellent scaffolds for cells to adhere to. 
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Fibrin is formed by the interaction of fibrinogen, a soluble plasma protein, and thrombin, 
a clotting enzyme. The structure of fibrin makes it a key material in the formation of 
blood clots and promoting wound healing in damaged tissues. Fibrin also has bioactive 
properties that recruit other cells to the tissue injury site, triggering cell adhesion. It also 
secretes various growth factors beneficial to vessel growth (Laurens et al., 2006). 
Because fibrin plays a key role in vasculogenesis in the body, its inclusion in 
vasculogenic models is important. While collagen is a readily available material with 
promising results, fibrin is used more frequently most likely due to its unique properties 
that highly encourage new vessel growth (Peterson et al., 2014). 
The density of the ECM is an important factor in terms of vessel morphology and 
functionality within a microvasculature network. In a fibrin ECM a higher concentration 
of fibrinogen results in an increased number of branching vessels but decreased average 
branch diameter and length. In contrast, a lower concentration of fibrinogen present in the 
ECM results in fewer branching vessels with larger lengths and diameters (X. Wang et 
al., 2018). These same results are recapitulated in collagen ECM as well (Edgar et al., 
2014). Fiber alignment has an impact as well as it affects vessel alignment due to contact 
guidance. Cellular traction forces can create aligned ECM fiber bundles from a cell 
aggregate during initial growth and development. Individual cells can even have an 
impact on fiber alignment and organization (Little et al., 2000). This structured ECM can 
then guide cell migration and the resulting shape of the microvasculature network.  
Vasculogenesis depends on different biomechanical forces generated by fluid 
flow. The most dominant biomechanical force is shear force from blood flow. This shear 
stress decreases vascular permeability by enhancing barrier functions of the endothelial 
cells. It can also help to narrow vessel walls, improving the overall stability of the 
vasculature. In general, forces generated from blood flow in the body can help determine 
the growth and shape of a vascular network. On a cellular level, shear forces from the 
blood flow can directly impact the cell morphology with cells elongating and orienting 
themselves along the axis of flow. The migration pattern of cells is also affected by fluid 
shear stress. Studies have shown that both intramural shear stress and transmural flow 
through the endothelium above a certain threshold can activate endothelial cells to begin 
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sprouting into the ECM independent of other outside factors (X. Wang et al., 2018). Gene 
and protein expression of endothelial cells can be affected by the forces of fluid flow as 
well. (Nakajima & Mochizuki, 2017).  
Endothelial cell density plays a critical role in vessel development as well. There 
needs to be a high enough cell density for cells to adequately communicate and 
anastomose with nearby cells to create a perfusable microvascular network. Branch 
length, diameter and area fraction of a vascularized region all increase with increased 
endothelial cell density (Whisler et al., 2012). Other mechanical properties such as pore 
size, gel permeability and fiber diameter and stiffness can play a role in vessel formation.  
Paracrine signaling from co-culturing the endothelial cells with other types of 
cells such as fibroblasts contribute to vascular network stability and vessel coverage area 
(Tronolone & Jain, 2021). Other co-cultures with stromal cells such as pericytes have 
found that the number of branches, average branch length, percent vascularized area and 
average vessel diameter can be influenced as well (X. Wang et al., 2018) It has also been 
reported that when endothelial cells are co-cultured with other cell types, resulting 
microvasculature can remain viable for longer periods of time compared to 
microvasculature with only endothelial cells present (Whisler et al., 2012). 
Section 1.4 – Growth Factors  
The presence of growth factors can have a large effect on vessel development and 
growth into a perfusable network. They’re secreted by endothelial cells to stimulate 
cellular growth, proliferation, and differentiation.  (X. Wang et al., 2018). The specific 
response of endothelial cells to growth factors can be complex as each individual growth 
factor has its own unique role in the formation of new vessels. For example, VEGF is the 
most pro-angiogenic growth factor involved in the process of new blood vessel growth. It 
regulates endothelial cell migration and proliferation and is important the growth of and 
development of endothelial cells as it regulates sprouting and tube formation of the cells. 
VEGF molecules interact with cell surface receptors to initiate a complex signaling 
pathway. A cascade of downstream proteins is activated leading to the pro-angiogenic 
effects of VEGF. VEGF is the most important growth factor as its necessary for normal 
vascular morphogenesis to occur. Multiple studies have shown that when the VEGF gene 
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in mice is deleted, vascular defects are prevalent as well as various cardiovascular 
abnormalities. (Vailhé et al., 2001).While VEGF may be the most important growth 
factor in vasculogenesis, other growth factors can enhance vessel development when 
combined with VEGF.   
Spingosine-1-phosplhate (S1P) is an endothelial cell chemoattractant involved in 
regulating endothelial cell proliferation and cell mobility. It promotes motility and 
migration of endothelial cells. S1P also plays a key role in endothelial cell assembly into 
tubular structures and cell-cell junction formation (Takuwa et al., 2010). Phorbol 12-
myristate 13-acetate (PMA) is another growth factor that primarily aides in endothelial 
cell proliferation and overall vascular network formation in terms of lumen formation and 
stabilization (van Duinen et al., 2019). PMA also enhances morphological changes in 
endothelial cells and increases cell motility (Tanaka et al., 2000). 
Based on results from angiogenic assays, combining growth factors has a 
synergistic effect on the forming vasculature improving vessel density, length, diameter 
and overall integrity of the vessel compared to the use of single growth factors. For 
example, since PMA causes endothelial cells to proliferate at a higher rate, S1P can act 
on more cells causing greater cell motility and an overall higher rate of anastomosis. 
However, to induce functional, multicellular sprouting growth factor amounts need to be 
balanced. Too much S1P compared to PMA can lead to too much cell migration without 
enough cells to form fully functional, intact vessels. The overall magnitude of the amount 
of balanced growth factors also plays a role in angiogenesis with larger magnitudes of 
S1P and PMA resulting in larger vessel diameter (W. Y. Wang et al., 2020). Other 
angiogenic studies have shown that when PMA and S1P were used in combination with 
VEGF, vessel sprouting was increased compared using VEGF with either PMA or S1P 
alone (van Duinen et al., 2019). 
While the growth factors involved in the formation of new blood vessels have 
many similar effects on endothelial cells, each growth factor is molecularly different and 
can have varying unique effects on vascular development. When used in combination 
growth factors can combine their pro-angiogenic potential and increase vessel 
development and angiogenic sprouting compared to using growth factors individually or 
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in partial combinations. Limited studies have been done in vasculogenic assays, but 
results should be recapitulated from the angiogenic studies as angiogenesis and 
vasculogenesis are both processes that involve vessel growth and development.  
Section 1.5 Vasculogenesis in Disease States  
As with any complex biological process, cellular mechanisms can get disrupted 
and vasculogenesis can become dysregulated. One example of this dysregulation is 
proliferative vessel formation in cancerous tumors. Tumors and vasculature have a 
dynamic relationship as tumors are highly dependent on a functional blood vessel 
network for a constant supply of nutrients and oxygenation as well as a mode of 
transportation. As tumors grow, their need for nutrients and oxygen increases 
enormously. To keep up with this ever-growing need, tumors work to expand the 
microvasculature network in the tissue they reside in by expressing pro-angiogenic 
factors. Overexpression of these factors leads to disorganized, tortuous blood vessel 
networks (Siemann, 2011). The irregular vessel shape and diameter restricts blood flow 
to the tumor causing hypoxic conditions which triggers the recruitment of EPCs. Tumor 
cells as well as surrounding endothelial cells release higher concentrations of VEGF 
which further promotes the migration of EPCs to the tumor site. (Dimberg et al. 2020) 
Higher levels of VEGF were found to correlate with the number of recruited EPCs (Balaji 
et al., 2013). Once at the tumor site, EPCs work to remodel the tumor environment with a 
chaotic, ever expanding network of microvasculature. 
Research in tumor blood vessel formation via angiogenesis comprises a majority 
of the research in the vascularization of tumors. The study of vasculogenesis is largely 
neglected in this context. This is because tumors normally under-go vascularization by 
angiogenesis. However, when angiogenesis is inhibited, tumors actively recruit EPCs and 
undergo vasculogenesis. A myriad of anti-angiogenic drugs has been developed to 
combat tumor vascularization. While these drugs show promise, tumors become resistant 
to anti-angiogenic therapy with time. Since tumors can also form a blood supply from 
EPCs, they do not have to completely rely on angiogenesis. Vasculogenesis is the 
systematic backup plan for tumor vascularization. This has yet to officially be established 
but evidence suggests that CD11b+ myeloid cells, which are key in the vasculogenic 
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pathway, are responsible for resistance to some of these anti-angiogenic therapies 
(Brown, 2014). While less common, vasculogenesis in tumor vasculature development is 
still an important area of research to better understand how tumors and their vasculature 
work.  
Tumors do not remain static, as cancer cells can metastasize all over the body. 
Cancer cells can break away from tumors and enter the circulatory system though the 
process of intravasation. Once in the circulatory system, they can travel to other regions 
of the body. Once a cancer cell attaches to a blood vessel wall it can extravasate out into 
a secondary tissue site (Fig. 2). Here the cancer cell will start to divide and multiply until 
another tumor is formed (Tsai et al., 2017). How successful cancer cells are at 
metastasizing or how well tumor growth and development can occur is dependent on how 
well tumor cells can recruit normal tissue cells, such as endothelial cells. It is vital to 
understand the complex relationships between normal tissue cells and tumor cells so we 
can develop more informed approaches to disease management.  
Vasculogenesis is also dysregulated in diabetes through tissue ischemia. Diabetes 
reduces the number of EPCs and their functionality (Georgescu, 2011). Hyperglycemia 
and insulin resistance promote this endothelial dysregulation by blocking specific 
signaling pathways responsible for the mobilization, migration, and ability of EPCs to 
Fig. 2 A cancerous tumor with proliferative vessel dysregulation and the metastatic 
process of tumor cells. (Biorender). 
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undergo vasculogenesis. Several in vitro studies have shown EPC populations from 
diabetic patients have a reduced capacity to form tubes. This complicates the 
neovascularization of ischemic tissues and other damaged tissues. Endothelial 
dysfunction results which can lead to cardiovascular complications such as myocardial 
infarction, peripheral vascular disease and ischemic stroke. Vascular complications such  
atherosclerosis can occur as well. (Kolluru et al., 2012). 
The dysregulation of vasculogenesis plays a part in a variety of disease states. In 
cancer vessel formation can become greatly increased while in diabetes vessel formation 
is severely restricted. There is a clear need to improve our understanding of vessel 
development in the context of the dysregulation of vasculogenesis. 
 
Chapter 2 
Current Models of Vasculogenesis 
Section 2.1 Current Vasculogenic Models  
Endothelial cells were first demonstrated to form capillary like structures when 
plated on top of a reconstituted basement membrane extracellular matrix more than 20 
years ago (Arnaoutova et al., 2009). The endothelial cells attached themselves to the 
ECM and rapidly formed capillary like tubules over a two-dimensional surface. Since 
then, this tube forming assay has been used in a variety of applications including 
angiogenic factors, wound repair and tumor growth. This tube forming assay spurred the 
development of more advanced models of in vitro, three dimensional assays of blood 
vessel formation in across a wide range of applications including tissue engineering 
perfusable constructs, drug screening and development platforms and disease models of 
dysregulated vasculature.  
Engineering fully-perfusable microvasculature for engineered tissue constructs is 
a major goal in current medical research. To ensure proper function of tissue constructs, 
the microvasculature needs to be fully intact. This is vital to ensure the proper diffusion 
of nutrients and oxygen transport throughout the tissue construct. However, development 
of these constructs remains limited due to the inability to fully vasculature the tissues.  
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(Peak et al., 2015). Vasculogenic models that can accurately recapitulate endothelial cell 
development into adult vessels are of great use in studying the development of 
engineered tissue constructs. Many groups of researchers have investigated several 
models and methods for producing engineered microvasculature in a variety of areas. A 
large area of interest is tissue constructs for vascular bypass applications to mediate 
various cardiovascular diseases. However, there are still limitations of these models. 
Ischemic heart diseases are the leading cause of mortality and morbidity across 
the world resulting in 16% of the world’s total deaths. (World Health Organization, 
2020). Due to the huge burden of ischemic diseases, vascular conduits to reconstruct or 
bypass vascular occlusions are in high demand. Synthetic grafts for replacing the 
occluded vessels have been used since the 1950s but various complications routinely 
occur including low patency rates for smaller diameter vessels, increased risk of 
infection, repeated surgical interventions and restricted growth potential for the pediatric 
patients. The development of tissue engineered blood vessels (TEBV) helped to solve a 
lot of these problems (Song et al., 2018) . However, the fabrication methods used for 
larger vessels cannot be applied to the construction of microvasculature networks. These 
smaller vessels have lower blood flow velocities and different structural architecture 
requiring different design methods (Isenberg et al., 2006).  For example, for larger 
vessels, a singular vessel is typically needed for the clinical application where its growth 
is precisely controlled in scaffold-based methods. When smaller vessels are needed it is 
typically an entire vascular network required for the application (Song et al., 2018). 
Developing an entire network is more challenging then just creating a new vessel due to 
complicated architecture and lack of precise control over spontaneous growth.  
 Recent methods in the creation of microvasculature networks can be categorized 
into two strategies. In the top-down method the geometry and architecture of the 
microvasculature network are pre-designed and prefabricated before the introduction of 
endothelial cells. The second method is a bottom-up method which relies on endothelial 
cells to develop into new vessels through physiological mechanisms such as 
vasculogenesis. Both methods are used commonly in the development of engineered 
cardiac tissue due to the prevalence of cardiovascular disease. However, due to their 
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physiologic relevance, bottom-up methods have been studied more extensively. For 
example, the bottom-up method was used to develop a functional small diameter arterial 
replacement graft. Arterial tissue and stem cells combined with synthetic scaffolds to 
make tubular structures have been a heavy area of focus. These constructs have various 
chemical and mechanical stimulation, such as growth factors and  pulsatile fluid flow, 
applied to them to create a successful graft (Song et al., 2018). 
It is important for the developed engineered microvasculature to exhibit clinically 
relevant characteristics. Two of these physiologically relevant characteristics that are not 
fully developed in in vitro applications are the alignment of microvessels and lumen 
density. Alignment of microvessels more closely recapitulates native microvessel 
architecture in vivo and allows for the creation of natural inlet and outlet areas for full 
perfusion through the vascular network. In this space, Tranquillo et al. were able to 
achieve strong microvessel alignment through mechanically constrained, cell-induced 
fibrin gel compaction after vasculogenesis was allowed to occur (Fig. 3a). This 
demonstrated that cell-induced compaction can be used to align microvessels in a 
vasculogenic model to create a more physiologically relevant model with full vessel 
perfusion and oxygen diffusion through the tissues. Additionally, the presence of 
interstitial flow through the engineered tissues resulted in increased microvessel density 
compared to a control sample with no interstitial flow. This highlights the importance of 
dynamic flow conditions in developing vasculature. Another important finding was that 
interstitial flow can impact the lumen density and overall microvessel formation (Morin 
et al., 2014). 
Epithelial tissue constructs are a large area of interest as well. Voytik-Harbin et al. 
developed a novel in vitro multi-tissue interface model featuring tissue spheres 
encapsulating endothelial cells. Specifically, they produced human endothelial colony 
forming cell (ECFC) encapsulated tissue spheres which were directly embedded into a 
surrounding tissue environment (Fig. 3b). This experiment demonstrated how 
independent controlling of the ECM through matrix composition and density and cell-cell 
interactions directly affected vascularization of the tissue sphere and vascularization of 
the surrounding tissue environment (Buno et al., 2016). 
13 
 
 While vasculogenic models presented provide excellent platforms to develop 
more physiologically relevant tissue constructs through vascularization, more recent 
developments have been focused on vasculogenic assays in microfluidic platforms.  
 
Section 2.2 Microfluidic Devices in Vasculogenic Modeling  
Mechanical and chemical factors can be tightly controlled through microfluidic 
technology. The design, fabrication and application of microfluidic devices allows for the 
manipulation of fluids on a micrometer scale. The precise control of device geometry, 
biochemical gradients and mechanical stimuli gives microfluidic devices the ability to 
more closely mimic in vivo conditions. 
Early in vitro studies of vascular physiology relied on cell culture plates and 
hydrogels to grow endothelial cells. While these studies greatly increased our knowledge 
and understanding of vascular system functionality in both healthy and diseased tissue 
states, they did not accurately portray a physiologically relevant microenvironment 
(Wong et al., 2012). Now with microfluidic devices, a more relevant model of 
microvasculature can be created. Microfluidic devices provide a variety of advantages in 
the development of functional vasculature including better control over geometry, 
biochemical gradients, and mechanical stimuli (Haase & Kamm, 2017). In microfluidic 
Fig. 3. Examples of current vasculogenic models a) Custom chamber for vascular constructs to 
measure gel compaction and interstitial flow on various microvascular characteristics most notably 
vessel alignment and lumen density (Morin et al., 2014).  b) Design of a multi tissue spheroid with 





device, a channel provides a three-dimensional (3D) surface for cells to adhere to and 
create a 3D extracellular matrix. A 3D structure allows for a more physiologically 
relevant microenvironment compared to a 2D structure. Cells in a 3D environment are 
morphologically different and their cellular responses are different as well. For example, 
cells cultured on a 2D surface are flatter and more elongated. This affects various cellular 
processes like proliferation, apoptosis and gene and protein expression (Kapałczyńska et 
al., 2018). To get the most accurate data regarding cellular response, the cells need to be 
in an environment that most closely recapitulates their native environment.  Another key 
feature of microfluidics is the ability to continuously perfuse fluid across the developing 
vasculature. This continuous fluid flow allows for a more constant supply of nutrients and 
removal of waste products. By fine-tuning the fluid shear stress, cell morphology and 
orientation are precisely controlled, impacting the resulting overall microvascular 
network. This can help the network last over an extended time period. 
Besides making in vitro models more physiologically relevant, microfluidic 
devices also operate on a small, higher throughput scale. This helps reduce consumption 
of expensive reagents and generation of waste. Most importantly, the small dimensions of 
the device helps to recreate the same temporal and spatial features found in vascular 
microenvironments (Hasan et al., 2014). 
There are three main techniques in the in vitro vascularization of microfluidic 
devices 1) endothelial cell (EC) lining based methods 2) vasculogenesis and 
angiogenesis-based assays and 3) hybrid methods. Endothelial cell (EC) lining methods 
typically begin with a 3D printed vascular mold structure (Fig. 4a). Cells are injected into 
the preformed vessel structures and allowed to form a monolayer on the channels of the 
microfluidic device. Microvasculature geometry and dimensions can be tightly 
controlled. However, the complexity of microvasculature networks is not recapitulated in 
this method. It is also difficult to form small, intricate capillary networks. This is due to 
the small diameters of the capillaries and the high density of endothelial cells  (X. Wang 
et al., 2018). When perfusing the channels with cells, the cells will block the small 
vessels eventually halting perfusion. The physiologic relevance is restricted in this type 
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of model because in vivo conditions cannot be completely replicated so they are limited 
when trying to uncover complex mechanisms of vessel development. The second method 
for in vitro vascularization is the process of vasculogenesis and angiogenesis, which can 
increase the complexity of a developed microvasculature network. Microstructures such 
as the preformed channels in the EC lining methods are not needed to help guide the 
formation of a microvasculature structure. Cells undergo self-assembly within the ECM 
similarly to the process in vivo and create a more physiologically relevant model of 
vasculature (Fig. 4b). While multiple vascular models have been successful in vessel 
development, models that allow vasculogenic self-assembly through the distribution of 
endothelial cells in a specified ECM have been the most promising. This is because 
through self-assembly, the endothelial cells can create a more physiologic vascular 
structure that more closely resembles in vivo conditions (X. Wang et al., 2018). As an 
example of this method, Kamm et al. designed a five-channel microfluidic device in 
which human umbilical vascular endothelial cells (HUVECs) were embedded in fibrin 
gels and cultured along human lung fibroblasts in the adjacent channels with channels of 
media running between them (Fig. 4b) (Whisler et al., 2012). 
The final method of in vitro vascularization is hybrid methods. Hybrid methods 
combine several vascularization methods and offer more control over the vasculogenic 
process through the manipulation of factors within the microenvironment (X. Wang et al., 
2018). For example, Wang et al. developed a microfluidic device model that incorporated 
multiple vascular development methods such as the EC lining method, vasculogenesis, 
angiogenesis and anastomosis. After sufficient vascular network development had 
occurred in the central tissue chamber via vasculogenesis, endothelial cell lining along 
the channels of the device was done. The outside channels were meant to represent the 
artery and vein of a capillary network. Angiogenesis was then allowed to occur which led 
to anastomosis between the endothelial cell lined outer channels and the capillary 
network ensuring interconnectivity (X. Wang et al., 2016). 
Vasculogenic models using microfluidic platforms have important clinical 
applications. For example, they can be used to develop microtissues. Hsu et. al. designed 
a microfluidic model to develop multiple human microtissues in parallel by controlling 
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mechanical stimuli such as interstitial flow. They used the device to induce 
vasculogenesis to create continuous microvascular networks across the microtissues (Fig. 
3c). 
Besides tissue engineering applications, microfluidic devices have a wide variety 
of other applications in microvasculature related areas. For example, devices can also be 
used for drug testing applications and used for in vitro modeling of dysregulated  
  
Fig. 4. Examples of current vascular modeling methods and applications using microfluidic platforms 
a) Endothelial cell lining method in preformed microfluidic channels (X. Wang et al., 2018). ( b) (i) 
Multi-channel microfluidic device design that relies on vasculogenesis (ii) Developed, fully perfused 
microvasculature network. (Whister et al., 2012).  c) Vascularized microtissues on a microfluidic 
model d) Microfluidic drug screening and development platform (Hsu et al., 2013) d) Biomimetic anti-
tumor drug screening platform (Shi et al., 2019). e) Microfluidic device with organ specific vasculature 
for metastatic cancer cell studies. (Arrigoni et al., 2016). 
 
c Pronagiogenic factors are overexpressed leading to disorganized, tortuous blood 











screening platform for measuring the transportation of drug molecules through the 
microvasculature. (Fig. 4d). The objective of the study was to determine the effect the 
microvasculature had on the efficacy of the drugs. Previous studies done by this group 
indicate the endothelial cell monolayer is an obstacle for drug transportation (Shi et al., 
2019). This is important as a physiological relevant model needs to incorporate this 
microvasculature component into the design of the platform. With more physiologically 
relevant models, drugs can be tested more accurately in a clinical setting to fully 
understand the effect of different drug concentrations and combinations of drug therapies 
before being introduced into the patient. Using microfluidics in drug studies such as this 
one can be advantageous due to high throughput nature of microfluidics. This allows 
many drug combinations can be tested simultaneously saving time and resources.   
Microfluidic devices can model vasculature in disease states and help elucidate 
vascular dysregulation on a cellular level. Several studies have produced organ specific 
microvasculature to investigate tumor cell extravasation and the metastatic process (Fig. 
4e) (Arrigoni et al., 2016). This type of model can help demonstrate how endothelial 
cells, immune cells and other cells along with the ECM can influence the progression of 
cancer. In a microfluidic device, different cell types can co-exist by compartmentalizing 
the different microenvironments. This co-culture design allows the complex process of 
metastasis to occur over the intricate, physiologically relevant environment. For example, 
breast cancer cells can be present in one microenvironment and connected to a bone 
microenvironment through a microvasculature network (Glaser et al., 2020).This allows 
the model to be more physiologically relevant as cancer cells would be traveling through 
a complex network of blood vessel during metastasis. To fully recapitulate the metastatic 
cascade, a functional microvasculature network needs to be incorporated along with the 
3D tumor model. Metastasis relies on vasculature to carry tumor cells throughout the 
body. With an intricate model of tumor metastasis important stages of cancer progression 
such as cancer cell intravasation and extravasation can be closely investigated.  
Modeling the process of vasculogenesis and optimizing conditions for functional 
vasculature is important to understand how blood vessel formation can help with the 
perfusion of engineered tissue constructs. Vasculogenic models have increased our 
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understanding of vascular biology and the formation of blood vessels in both embryonic 
development and adult vasculogenesis.  
Vasculogenic models are application dependent. Vasculogenic models for use in 
tissue engineering discussed in Section 2.1 are excellent models for the development of 
larger tissue constructs. For smaller tissue constructs and applications outside of tissue 
engineering, microfluidics provides an excellent platform.  
Section 2.3 Current Microfluidic Models on Factor Dependent Vasculogenesis  
To create microfluidic models of microvasculature, there are several key 
components of neovascularization that can be directly manipulated inside a microfluidic 
device as discussed previously. Many studies have been conducted on these specific 
components in angiogenic assays, but limited studies have been conducted in 
vasculogenic assays. Kamm et al. analyzed HUVEC seeding density and fibrin density in 
microfluidic devices to help uncover factors that control network morphology of 
developing vessels. It was found that a higher cell seeding density allowed for increased 
branch length, diameter and area fraction of the vascularized region. Additionally, a 
higher fibrin concentration led to an increased average branch length and diameter of the 
vessels. Area fraction of the vascularized area seemed to be unchanged with changing 
fibrin concentrations (Whisler et al., 2012). By manipulating factors that affect 
vasculogenesis, the most ideal conditions can be determined for fully perfused 
vasculature.  
Since angiogenic models have been studied more than vasculogenic ones, more 
angiogenic growth factors and consequently their effects on the vasculature have been 
understood. Song et al. identified two distinct growth cocktails that resulted in the most 
robust and multicellular endothelial cell development. They determined VEGF had a 
negligible effect on cell sprouting when used alone and S1P alone only triggered 
increased cell migration. However, when different growth factors were combined, cells 
produced greater multicellular sprouting (Song et al., 2018). In another angiogenic 
sprouting assay, Hankemeier et al. also tried to uncover ideal growth factor combinations, 
with VEGF, PMA and S1P. Again, as reported by Song et al, when acting alone each 
growth factor did not induce angiogenic sprouting. When combined, VEGF, PMA and 
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S1P induced angiogenic sprouting with the sprouts fully traversing the gel channel and 
showing clear lumen formation (van Duinen et al., 2019) Few vasculogenic assays have 
explored the effects of growth factors and their various combinations on vessel growth 
and development. Kamm et al. used VEGF and S1P to understand their effect on 
developing vascular networks. They found the addition of these two growth factors 
together resulted in branches that were shorter in length and smaller in diameter. With 
smaller vessels, less area was covered by the developing network. They also co-cultured 
the endothelial cells with fibroblasts which improved vessel development. An important 
finding was that when co-cultured together with fibroblasts and stimulated by VEGF and 
S1P together, network stability of the microvasculature network was greater and 
vascularized space was increased compared to a control with no growth factors. Using 
growth factors alone in vasculogenic assays, based on this one study, decreases vessel 
development, but when used in a co-culture with fibroblasts, vessel development 
increases (Whisler et al., 2012). 
Some existing models of vasculogenesis, while able to produce fully functional 
microvasculature networks, lack the precise control over fluid dynamics, device geometry 
and biochemical gradients. Vasculogenic microfluidic models that do have this precise 
control have not been studied as closely as angiogenic assays and therefore a complete 
understanding of the process is lacking. For example, evidence on the temporal control of 
growth factors on developing vasculature remains to be fully elucidated.  
The objective the project outlined here is to enhance the understanding of how 
various factors like endothelial cell density, ECM composition and density, growth factor 
solutions and flow control all influence the development of a microvasculature network 
within a single microfluidic platform. The motivation is also to use this platform in future 
endeavors in the Wood Lab where a physiologically relevant, fully perfusable, 
microvasculature is needed.  Based off previous findings it is predicted that a fibrin ECM 
with a higher initial cell-seeding density and a growth factor solution of multiple growth 
factors will induce a fully perfusable microvasculature network. Additionally, it is 
predicted that a microfluidic device with fluid flow control through the channels will 
allow for increased vessel growth and development.  
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Chapter 3  
Methods  
Section 3.1 Cell Culture and Preparation  
HUVECs were chosen due to their commercial availably, ease of use and proven 
success in vasculogenic assays. HUVECs were seeded and cultured on gelatin coated 
75cm2 cell culture flasks with Lonza EGM media in a 5 % C02 controlled incubator at 
37°C. Cells at passages 4-6 were used. The Lonza EGM media contained endothelial cell 
basal media (500mL) and an assortment of additional components including 10mL of 
FBS, 0.2mL of hydrocortisone, 2mL of hFGF, 0.5mL of VEGF, 0.5mL of R3-IGF-1, 
0.5mL of Ascorbic Acid, 0.5mL of hEGF, 5mL of GA-1000 and 0.5mL of Heparin. 5mL 
of Antibiotic-Antimycotic was added as well to prevent bacterial and fungal 
contamination. HUVECs were used due to their commercial availability, ease of use and 
previous success in vasculogenic assays.  
Cells were used at or very close to 100% confluency. They were washed twice 
with Hank’s Balanced Salt Solution (HBSS) and trypsinized to detach the cells from the 
bottom of the flask. Once neutralized with EGM media, the cell solution was centrifuged 
at 1000rpm for 5min. The supernatant was aspirated and cells were resuspended in 5mL 
of EGM media. 10uL of the cell solution and 10uL of trypan blue were mixed and placed 
on a cell counting slide. Once cells were counted, desired amounts of the cell suspension 
were aliquoted based on the number of cells needed and centrifuged again. Cell viability 
was always above 90%. Cells tested negative for mycoplasma.  
Section 3.2 ECM Gel Fabrication  
Collagen gels were prepared with 9.1mg/mL collagen stock, EGM media, DPBS 
and NaOH to get a final collagen concentration of 6mg/mL. The collagen mixture was 
kept on ice for 2 hours to avoid premature polymerization. Cells were then mixed into 
collagen aliquots in small tubes and contents were gently disturbed and inverted to 
combine. If being mixed with Matrigel, the collagen and cells would be added to the 
Matrigel and mixed for both the well plate and microfluidic devices. Well plates and 
devices were incubated for 30 minutes at 37°C to allow for gel polymerization. With 
21 
 
Matrigel only assays, Matrigel was pipeted into the well plate (50µl) and the cells were 
seeded directly on top.  
Fibrin gels were created by first dissolving fibronectin (Sigma Aldrich, Bovine 
Plasma) in DPBS at a concentration of 10mg/mL. After allowing the fibrinogen to get 
into solution, the solution was sterile filtered with a .22µm filter to ensure sterility. After 
the aliquoted amount of fibrinogen solution was mixed with cells, it was added to a 0.6uL 
aliquot of thrombin (Sigma-Aldrich, Bovine Plasma) (100U/mL) and quickly loaded into 
a well plate or the center channel of the device. Final fibrin concentration was 9mg/mL. 
Well plates and devices were incubated for 30 minutes at 37°C to allow for gel 
polymerization. 
Section 3.3 Device Design and Fabrication  
 The microfluidic device used in this work is a three-channel device with 
trapezoidal posts in between the media channels and the central gel channel. The gel 
channel is where the fibrin or collagen ECM and cells are injected. The two flanking 
media channels provide nutrient delivery and a pressure driven flow across the gel/media 
interface. The 200µL of media placed in the inlet channels of the device flows through 
the device and towards the empty media outlet channels. The flow is sustained until an 
equilibrium is each reached between the media in the inlet pipet tips and the outlet pipet 
tips.  
The microfluidic device was designed using AutoCAD and negative pattern 
masks were printed (Fig. 5a and Fig. 5b). A 115µm layer of SU-8 photoresist was coated 
onto silicon wafers and the pattern was photopolymerized onto the wafers creating a 
raised design. PDMS and a curing agent were mixed at a 10:1 ratio and poured onto the 
wafers. They were placed in a degassing chamber for an hour and then baked for 2 hours 
at 75°C. Devices were cut out and biopsy punched to create inlet and outlet ports for the 
three channels. Tape was used to clean the devices of debris. Devices and glass slides 
were plasma treated for 2 minutes and quickly bonded together. They were placed on a 
hot plate overnight at 120°C (Fig. 5c). The goal with this device was to create a 
physiologically relevant model of endothelial cells undergoing vasculogenesis, with flow 




PDMS coated glass slides were made by spreading PDMS across a transparent 
sheet of paper and laying the glass slides down firmly on top of the PDMS layer to 
eliminate bubbles. Slides were left to sit overnight and baked the next day at 75°C for 2 
hours. Devices were pulled apart and tape was also used to clean the slides of debris. 
PDMS coated glass slides and devices were bonded in the same manner as mentioned 
previously. 
Several durations of plasma bonding were tested at two different power settings to 
determine the optimal bonding conditions for a PDMS coated glass slide and PDMS 
devices after bonding issues had occurred. Bonding groups at 50% power with a duration 
of 2 minutes and 1.5 minutes seemed to be the most ideal. Moving forward a plasma 
bonding time of 2 minutes at 50% power was used.  
Fig. 5 Design of microfluidic device a) CAD design of the microfluidic device platform b) Magnified 
post design of the microfluidic device with direction of media flow through the device. c) Microfluidic 
device with PDMS device plasma bonded to a glass slide with inlet/outlet media channel and gel 
channel pipet tips d) Anatomical model of microfluidic device design (Biorender). 
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To create more resistance for fluid flow, leading to increased flow over a longer 
time period a secondary resistor was incorporated into a trial design. Two secondary 
resistors also made of PDMS following the same procedure as above, were attached to 
each inlet port of the devices by a 6cm length of 0.02mm diameter tubing and plasma 
bonded to glass slides. A 1mL pipet tip was inserted into each media outlet and each inlet 
of each of the secondary resistors. For devices without the secondary resistors, 200µL 
pipet tips were placed in the same manner in the devices. Due to the large amount of 
effort for one device, this design was not scalable for the number of devices needed. For 
the final design the second resistor was not included and only used as a trial design.  
Section 3.4 Endothelialization of Media Channels 
Vessel formation was allowed to occur for 96 hours before endothelialization of 
the media channels. The secondary resistor and tubing were disconnected from the inlets 
and 200µL pipet tips were inserted into the inlets of the device. 10µL of EGM media 
with 10µg/mL of fibronectin was loaded into both media channel inlets. Devices were 
incubated in static conditions for 1 hour to allow the fibronectin to fully coat the 
channels. Next 10µL of a 12 million cells/mL cell solution was loaded into each of the 
media channel inlets in all devices. Devices were incubated for 30 minutes to allow for 
cell adhesion to the channel walls. This was repeated for all devices again with 10µL of 
cell solution to ensure full cell coating of the channels. The 200µL pipet tips at the inlets 
were removed and the secondary resistors and tubing were reconnected with the devices. 
1mL of media was added to each of inlet pipet tips. 
Section 3.5 Growth Factor Experimental Setup  
Growth factor solutions were prepared 24 hours in advance according to the 
manufacturer’s instructions. VEGF stock solution was prepared at .1µg/mL (murine 
VEGF, Peprotech) in cell culture water. S1P stock solution was prepared at 1mM in 
Methanol (Sphinogosine-1-Phosphate, Sigma Aldrich) and PMA stock solution was 
prepared at 2µg/mL in DMSO (Sigma Aldrich). Growth factors were all diluted in EGM-
2 media with no VEGF added at the following concentrations: 50ng/mL for VEGF, 
50ng/mL for PMA and 500nM for S1P.  
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The objective was to determine which combination of growth factors has the 
largest impact on vessel growth and development. As a negative control the VEGF 
negative media was used on a group of devices. It was prepared the same way as 
described previously, just without the 0.5ml of the VEGF to allow for absolute control 
over the growth factor addition to the experimental groups. Each experimental group 
(Table 1) had three devices and was replicated three times. After devices were injected 





Group Growth Factor Combination 
1 Negative Control 
2 S1P + PMA 
3 VEGF + PMA 
4 VEGF + S1P 
5 VEGF + S1P + PMA 
Table 1: Experimental Growth Factor Combinations  
 
Fig 6.  Experimental set up of growth factor experiments. Devices were loaded with fibrin ECM and 
HUVECs. Two experimental branches were set up, with one group receiving growth factor 
solutions right away at day 0 until day 5 and the other group at day 3 until day 5. Devices were fed 
twice at day until they were imaged on day 5. (Biorender). 
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pushed into both outer media channels until it reached the outlet. 200µL of respective 
media was added into each inlet pipet tip and the outlet pipet tips were left empty to 
create a pressure driven flow.  
To test whether the timepoint at which growth factors are added to the devices 
impacts vessel development, the experiment was replicated with the exact same setup and 
conditions with growth factors being added 3 days after gel polymerization (Fig. 6). Up 
until day 3 devices in the delayed application group were given the control EGM. At day 
3, after sufficient vessel development had occurred, the experimental groups in the 
second branch began to receive their respective growth factor solution instead of the 
standard VEGF negative media. Devices were kept in plastic boxes with 10µL of DPBS 
in the bottom of the box to prevent device dehydration. Respective media for each 
experimental group was replenished in devices twice a day for 5 days. After 5 days 
growth media was removed from all devices and stained with a Calcein solution to 
highlight the microvasculature network. Calcein stock solution (10µg) was diluted in 
10mL of DPBS. To ensure proper dispersion of the Calcein across the gel channel, 
200µL of the stain solution was placed in the inlet and outlet port on the same side of the 
device. This allowed for the Calcein stain to dissolve across the gel to the other media 
channel. The Calcein solution was left to sit on the devices for 30 minutes before 
imaging.  
Section 3.6 Imaging and Statistical Analysis 
  Images were taken on a Zeiss Microscope and processed using ImageJ software. 
A standardized area of the central gel channel was used for all microvasculature network 
images where data was collected. After image processing, images were analyzed using 
Angiotool imaging software to map the microvasculature network. 
 The addition of growth factors experiment was replicated three times with 3 
replicates per condition. The results are presented as mean + standard deviation. A one-
way ANOVA test was performed for the comparison of the control to each individual 
growth factor. All statistical analyses were done on GraphPad Prism software. A p-value 
of less than 0.05 was considered to be statistically significant.  
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Chapter 4  
Results  
Section 4.1 Optimization of a Microvasculature Network  
To fully understand the best conditions for vessel growth in an in vitro 
environment in a more streamlined manner, experiments were done first in well plates 
with the motive to move to microfluidic devices when a best method for vessel growth 
was uncovered.  
Section 4.1.1 Fibrin Gels Create an Environment for Vessel Formation  
Optimization in the well plate started with finding the ideal cell concentration 
conditions in a collagen ECM. Collagen was chosen for the first iteration of experiments 
because of its wide use and success in vasculogenic assays. Cell concentrations of 3 
million cells/ml, 3.5 million cells/ml and 4 million cells/ml were tested. 50ul of collagen 
gel mixed with cells were placed in a 96 well plate with 100ul of media on top. Media 
was changed every other day and images were taken every 24 hours.  In all of the 
conditions cells failed to adequately grow and anastomose even by the 96 hour mark. 
HUVECs were also seeded with fibroblasts in varying ratios (2:1, 4:1 and 5:1) but several 
experiments showed no change in growth of the HUVECs in terms of vessel 
development.  
 To show the cells had the ability to form vessels, cells were seeded on top of 
Matrigel at varying cell concentrations (4 million cells/ml and 8 million cells/ml). 
Matrigel is a murine tumor extract, composed of ECM material and basement membrane 
proteins (Stryker et al., 2019). In both concentrations, cells showed vessel network 
formation in the typical cobblestone like structure, at the 24-hour mark (Fig. 7a.) While 
promising, the use of Matrigel would not be feasible to use in the device design presented 
here for several reasons. First Matrigel is not as biologically relevant as other ECM 
materials as it was developed from a murine sarcoma. Second, when mixed with 
Matrigel, cells failed to adequately grow and anastomose to create vessels. To be 
incorporated into the device, the HUVECs would have needed to be mixed with the 
Matrigel. While it is not fully clear why the cells were able to undergo great vessel 
formation when seeded on top of the Matrigel and not mixed in, it can be speculated. We 
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hypothesize the cells were most likely able to form tubular structures more easily seeded 
on top because they were on a 2D surface. Matrigel assays were developed to imitate the 
ECM in a two-dimensional manner and are typically used in angiogenesis assays. The use 
of Matrigel in vessel development seemed unable to translate to a 3D environment for a 
vasculogenic assay. The cells also covered less of an area because of the dimensionally of 
a 2D surface and most likely had an easier time to anastomose.  
To overcome the lack of cell growth in collagen, collagen and Matrigel were 
mixed in different ratios to see if a combination of the two would lead to vessel 
formation. Collagen and Matrigel were used at 100% collagen, ratios of 1:3, 1:1, 3:1 and 
100% Matrigel in a tube formation assay. A ratio of 1:1 demonstrated the most potential 
to induce cell growth and vessel development. As evidenced in (Fig 7b.) tubular 
formation of the cells indicated a collagen and Matrigel combination led to more cellular 
growth and vessel development compared to collagen alone. While promising, the 
combination of collagen and Matrigel still did not show the vessel network development 
desired.  
Fibrin was introduced as a new ECM material to use. Fibrin gels were created at 
concentration of 9mg/mL. Compared to a 1:1 ratio of collagen/Matrigel, the fibrin 
allowed the cells to grow more and undergo vessel formation (Fig. 7c). At 96 hours, gels 
were stained with Calcein and DRAQ5 to show the endothelial cell development into 
microvasculature. (Fig. 7d). Qualitatively the vessel diameter appeared to be increased as 
well in the fibrin compared to the collagen/Matrigel. Due to the nature of using bulk gels 
in a well plate, the 3D architecture of the assay made it difficult to obtain clear images of 
the vessel development and growth. It was hypothesized using a microfluidic device 
would decrease the thickness of the gel assay and result in much clearer images.  
After successful optimization in the well plates with fibrin gels, vessel formation 
in a fibrin ECM in a microfluidic device was the next step. A 1:1 ratio of collagen and 
Matrigel was again tested against fibrin. Like results in the well plate, collagen and 
Matrigel failed to supply an adequate environment for vessel formation evidenced by the 
failure of cell growth into tubular structures (Fig. 8a). In stark contrast to the 
collagen/Matrigel bulk gel, in the fibrin ECM, vessel formation was very prevalent and 
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vessel network development seemed increased in the devices compared to the well plate 
(Fig. 8b). This is most likely the result of the microfluidic technology used, specifically 
the fluid flow through the media channels. Qualitatively the vasculature network 
appeared more developed and robust in vessel size in the device compared to in the well 
plate. 
 As an additional step in the optimization of vessel development in devices and to 
assess further areas of experimentation, a higher concentration of VEGF was added to the 















Fig. 7. Experimentation with different ECM compositions in a standardized well plate a) HUVECs 
seeded on top of Matrigel at a concentration of 8 million cells/ml  b) Matrigel/Collagen combination in 
a 1:1 ratio with a HUVEC concentration of 9 million cells/ml c) Fibrin ECM with HUVECs at a 
concentration of 9 million cells/ml d) Fibrin ECM with HUVECs at a concentration of 9 million 












Qualitatively, preliminary results showed increased vessel network formation with the 
addition of VEGF compared to a control (Fig. 8c and 8d) and a point of investigation for 
the effect of growth factors on vasculogenesis in a fibrin ECM. The control did not have 
any additional VEGF added to the media, just the VEGF present in the EGM.  
To highlight the developed vasculature was able to form a perfusable network, a 
fluorescent bead flow assay was performed. Several beads were able to somewhat 
traverse the gel channel via perfused vessels, though the total number of beads able to 
traverse the entire gel channel was low. This is because beads were leaking underneath 
the gel from the media channels into the ECM.  
a) b) 
c) d) 
Fig. 8. Microfluidic device assays with 12 million cells/ml a) Collagen/Matrigel ECM where 
cells failed to form vessels b) Fibrin ECM supported the development of a microvascular network 
c) Microvascular network formation in fibrin ECM stained with Calcein d) Microvascular 
network formation in fibrin ECM with media supplemented with 50ug/ml of VEGF and stained 
with Calcein. Scale bars = 100um  
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Section 4.1.2 Endothelialization of Media Channels/PDMS Slides  
To solve the issue of bead flow underneath the gels, media channels were 
endothelialized to create a fully perfused vessel from the inlet to the media/gel interface. 
With a fully intact vessel, beads would not be able to escape underneath the gel and the 
vessel development within the gel could be more accurately assessed. Fibronectin was 
used to help the cells adhere to the device walls. Compared to a control with no 
fibronectin present, media with 10ug/mL of fibronectin allowed for much more cell 
adhesion (Fig 9a and 9b). PDMS coated glass slides showed slightly improved cell 
adhesion over glass slides. However, the addition of fibronectin to the EGM made the 
largest improvement in cell adhesion (Fig 9c and 9d). 
 We hypothesized that using a PDMS coated slide might prevent bead flow 
underneath the gels and allow for better cell adhesion along the media channels. While it 
did help with some cell adhesion it remained inconclusive if it impacted bead flow 
underneath the gel. The PDMS devices failed to adequately adhere to the PDMS coated 
glass slides in every instance. This resulted in devices becoming unbonded in the middle 
of an experiment and caused DPBS to leak in. It was decided that since the difference of 
cell adhesion between the PDMS coated glass slides and uncoated glass slides was 
minimal, glass slides would be used for further experimentation to ensure proper 
bonding.  
As a trial design for extended fluid flow, a two-resistor device set up was tested. The 
purpose of this design was to see if an extended time period of fluid flow from four hours 
a day to a fully 24 hours, impacted vessel development. Preliminary results indicated a 
negligeable difference in microvasculature development, but more testing needs to be 
done as the literature firmly states fluid flow leads to increased vessel network 
development.  
 After endothelialization of media channels, device design and PDMS coated slide 
experiments were completed we concluded that for the most ideal vessel formation and in 
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the interest of time, the channels would not be endothelialized for further experimentation 
and only glass slides would be used. However, the model described here could be 
developed further.  
As the final points of optimization, cell seeding density and ECM density were 
fine tuned. Initial seeding in the devices was at 12 million cells/ml. It was hypothesized 
that a higher seeding density would aide in vessel development. The cell concentration 




Fig. 9.  a) Control. Glass slide with no fibronectin b) Glass slide with channels perfused with media 
supplemented with 10ug/ml fibronectin c) PDMS coated glass slide with no fibronectin d) PDMS 
coated glass slide with channels perfused with media supplemented with 10ug/ml fibronectin. Scale 





was observed to be increased. Data is not shown as this was just a point of optimization 
between experiments. To be certain that a higher seeding cell density impacts vessel 
formation and growth further experimentation would need to be done.  
Section 4.2 Investigating the Effects of Growth Factors on a Microvasculature 
Network  
 Mixed results were seen in the images regarding proper calcein staining of the 
microvasculature. Specifically, the Calcein stain was not able to completely stain all the 
vessels throughout the gel channel in every device. It was hypothesized that the Calcein 
stain was not able to properly perfuse through the gel itself or the vessels were not 
developed enough or starting to degrade causing the calcein to not be able to travel 
through the gel via the vessels.  
 A permeability assay was performed to ensure that the Calcein stain was able to 
adequately perfuse through the fibrin gel. Fluorescent Dextran was diluted in 10mL   
DPBS and stained according to the Calcein staining protocol described in the methods 
section. Imaging showed that the dextran was able to fully perfuse through the gel, 
meaning the gel permeability was not the factor impacting the ability of the Calcein to 
stain the vessels. 
It was also hypothesized that the leftover media inside the channels could be 
preventing the stain from permeating across the gel to reach all the vessels. With trials 2 
and 3 of this experiment, 200µL of Calcein staining solution was pipeted into the upper 
left inlet port and placed in the incubator for 5 minutes. This allowed any remaining 
media in the device to be washed out. After this short incubation period 200µL of the 
Calcein stain solution was added to the corresponding upper outlet after remaining media 
was removed. With the calcein staining solution in one inlet-outlet pair, the calcein stain 
would be able to diffuse across the gel instead of just flowing through the media 
channels. To ensure complete staining of all the vessels in the gel channel, the same 
process was repeated in the lower inlet/outlet pair. Removing the media before staining 
with Calcein stain solution showed more complete staining of vessels than in trials where 




Data collection was focused on vessel percent area, average vessel length and 
total length. Microfluidic devices in the delayed application group where the growth 
factors were not added until after sufficient vessel development (day 3) showed greater 
vessel coverage area, average vessel length and total vessel length compared to the 
immediate application group (Fig. 10 and Fig. 11). This indicates that growth factors can 
Fig. 10.  Microvascular network development over a control group and four growth factor 
conditions in three different experimental trials. Scale bar = 100um 
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have a larger impact on vessel development if they are introduced later in endothelial cell 
growth. In experiment 1 in the immediate application group both average and total length 
were greater in the condition with the growth factor combination of S1P + VEGF. Results 
are not as clear as to which growth factor impacts vessel percent area the most. In the 
delayed application group vessel percent area and total vessel length were greater in the 
conditions with the growth factor combinations of VEGF + PMA and VEGF +S1P + 
PMA. The growth factor combination of VEGF + S1P +PMA resulted in the greatest 
average vessel length (Fig. 11b).  In experiment 2 in the immediate application group 
results indicate the growth factor condition VEGF + S1P + PMA results in the most 
vessel growth in term of vessel percent area and both average and total vessel area 
compared to the other growth factor conditions. However, the vessel development in the 
growth factor conditions did not significantly surpass the vessel development in the 
control which had no growth factors. In the delayed application group, all growth factor 
conditions except S1P +PMA seemed to increase vessel percent area, average and total 
vessel length. These results are also represented qualitatively (Fig. 9) Finally, in 
experiment 3 in the immediate application group, results were not completely conclusive, 
but they did indicate that all the growth factor conditions except S1P + PMA had slightly 
increased vessel development compared to the control.  In the delayed application group 
growth factor condition VEGF + PMA resulted in most increased vessel percent area and 
average vessel length. Results were inconclusive for the total vessel length.  
A one-way ANOVA statistical test showed that in vessel % area, the growth 
factor combinations of VEGF + PMA and VEGF + S1P + PMA were statistically 
significant from the control in the delayed application. They were also statistically 
significant from the immediate application to the delayed application (Fig. 13a). VEGF + 
PMA was also statistically significant for average vessel length and total vessel length in 
terms of the control and immediate to delayed application (Fig. 13b and Fig. 13c). 
Overall, these results suggest a common overall trend that VEGF and PMA in 
combination is needed for complete vessel development in a microvasculature network. 
In most cases without VEGF and PMA together, growth factor conditions failed to 
produce vasculature with increased vessel percentage area, average vessel length and 
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 total vessel length compared to conditions that did have VEGF and PMA together. The 
exact combinations of growth factors that lead to the most vessel development is unclear, 
but combinations of VEGF and PMA seem to repeatedly have a positive impact on vessel 
development. 
Fig. 11. Vessel development compared between two groups 1) Growth factor solutions added at 
Day 0 and 2) at Day 3 for all four growth factor conditions. Scale bar = 100um 
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In the conditions where PMA was present, more cell proliferation occurred in the 
media channels. On day 4 a few cells that had escaped the gel channel were seen in the 
media channel. By day 5, those few cells had proliferated to fill the entire channel with 
cells. In the conditions where PMA was not present, cell proliferation in the media 
channels occurred but not at the same magnitude as the conditions with PMA. This is an 
important factor to consider when endothelializing media channels.  
Chapter 5  
 Discussion 
Vascular network development and formation is enhanced through a defined 
extracellular matrix composition, specific combinations of growth factors and flow 
Fig. 12.  Experiments 1-3 in the immediate application of the growth factor combinations on day 0 
and in the delayed application of growth factors on day 3 as well as the individual performance of 
growth factors (n= 3) for a) vessel % area b) average vessel length and c) total vessel length. Graphs 



















control in a microfluidic device. Studies done here were able to show the importance of 
developing and studying microvasculature networks in the context of microfluidic 
Fig. 13.  Comprehensive analysis of vessel % area, average vessel length and total vessel length 
with a direct comparison between immediate and delayed growth factor application compared to 
a control. (n=9) Graphs are presented as mean + standard deviation.  * Indicates statistical 






devices. Experimentation demonstrated the finicky nature of endothelial cells in their 
development into a microvasculature network. Results can be used in the development of 
a fully perfusable, microvasculature network platform that can be used in 
experimentation in a variety of applications such as tissue engineering, drug screening 
and development or disease modeling.  
It was apparent that a precisely defining the extracellular matrix in terms of 
density and material used was necessary in order to produce quality vasculature. In both a 
well plate and in a microfluidic device collagen mixed with Matrigel failed to produce 
vessel growth while fibrin showed successful vessel growth. While collagen and fibrin 
have both been successfully used to produce microvascular networks, only fibrin showed 
success in the platforms tested here. It is possible the collagen may have been 
incompatible with the specific HUVEC line used. Future experimentation with a different 
HUVEC cell line would indicate if this was the case. Interestingly a co-culture with 
fibroblasts in the collagen gels did not make a difference in cell growth. Again this could 
be due to compatibility issues with the collagen gel used. It would be interesting to do the 
co-culture in the fibrin gels in the microfluidic device to see if they would enhance vessel 
development.  
It was also observed that increasing the initial endothelial cell concentration to 14 
million cells/mL resulted in more vessel development compared to smaller concentrations 
which agrees with previous studies and the literature. Additionally, the concentration of 
the fibrin was experimented with, it was clear a set fibrin concentration of 9mg/ml as 
prepared was the most ideal for vessel growth. When the fibrin concentration was 
lowered to even 5mg/ml the fibrin was not able to stay contained inside the central gel 
channel. A concentration of 7.5mg/ml did stay inside the gel channel, but vessel 
development was not as strong as the 9mg/ml fibrin concentration. However, a clear 
picture of the effects of changing ECM density on the developing vessels was not able to 
be elucidated here. 
Fluid flow control in a microfluidic model helped with vessel development. Vessel 
diameter and overall area was increased in the device platform compared to the standard 
well plate. While flow was present in the device, it only lasted for about two hours before 
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the pressure driven flow became equilibrated. This means each device was getting 4 
hours of fluid flow through the device each day since media weas changed twice a day. 
The limited flow through the device was due to the size of the pipet tips used (200µL). 
While helpful, the flow was a limiting factor of the platform.  Flow is important in the 
development of a microvasculature network because it controls growth and the over 
shape of the network. Blood flow in developing vasculature impacts cells in a variety of 
ways, for example through cell morphological changes and proliferation. These changes 
collectively impact the overall properties of the resulting microvasculature network and 
surrounding tissue. Without the incorporation of continuous flow in a vasculogenic 
model, the architecture of a microvasculature network would not completely recapitulate 
the physiological conditions inside the body.   
In future iterations of this platform, fluid flow conditions could be connected to a 
fluid pump system where the flow rate could be tightly regulated, and a precise and 
physiologically relevant interstitial flow rate could be applied. Without continuous fluid 
flow, other forces are most likely affecting growth factors to permeate through the ECM 
such as mass transfer. The higher concentration of growth factors flowing through the 
media channels diffuse through the ECM to areas where no growth factors are present. 
Future experimentation with this platform could look more closely at this mass transfer 
effect in the absence of continuous fluid flow. With continuous fluid flow it would also 
be possible to see microvessel alignment in the direction of flow.  
It was hypothesized that using a microfluidic device in place of a well plate would 
allow for clearer images to be taken of the resulting microvasculature networks. While 
still a 3D microenvironment, the ECM in the device was far less thick than the ECM in 
the well plate. Results showed using a microfluidic device platform did allow for clearer 
images to be taken.  
It was found the addition of growth factors in different combinations and added at 
different timepoints affects the development of the resulting vasculature in vessel percent 
area, average vessel length and total vessel length. The results from this experiment fill a 
noticeable hole in the literature regarding the impact of the timing of the application of 
growth factors in models of vasculogenesis. Here two groups were presented with the 
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various growth factor combinations, one group receiving them right after gel 
polymerization on day 0 and the second after sufficient vessel development on day 3. 
Across all three experiments it was clear that waiting until day 3 to add the growth factors 
increased vessel percent area, average vessel length and total vessel length. Vessel 
networks visually looked more intact and stabilized as well (Fig. 9)This is interesting as 
growth factors in vivo are present as the endothelial cells are developing into vessels, not 
after they have already formed. More experimentation and analysis will need to be done 
to fully understand why waiting to add growth factors until vessel formation has occurred 
results in more developed vasculature.  
Experiments demonstrated that specific combinations of growth factors can impact 
the quality and amount of vessel growth. Results here indicate that having VEGF  and 
PMA present in a growth factor combination is important for the overall development of 
a microvasculature network. This agrees with the findings of previous vasculogenic 
assays that included VEGF and PMA performed to assess the effects of growth factors on 
a developing microvasculature network. Another interesting result showed that adding 
the growth factors right away on day 0 decreased vessel percent area, average vessel 
length and total vessel length compared to a control with no additional growth factors 
added. Initially these results contradict themselves as the addition of growth factors is 
supposed to induce more vessel growth and development, not reduce it. However, a few 
studies have shown that when growth factors were added to endothelial cells without a 
co-culture like in the case presented here, vessel development was decreased compared to 
endothelial cells that were co-cultured with other stromal cells (Whisler et al., 2012). 
 It was predicted that growth factors conditions containing VEGF would increase 
overall vessel development and formation. Conditions containing PMA were predicted to 
have a large impact on vessel % area due to its role in endothelial cell proliferation. 
Conditions with S1P were predicted to have more vessel network branching as S1P plays 
a key role in endothelial cell migration through the ECM.  
Results indicated that when VEGF and PMA were present in a condition together, 
they were able to induce the most vessel development in terms of vessel % area, average 
vessel length and total vessel length. In this vasculogenic platform, S1P did not seem to 
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play a significant role in vessel development. To form any concrete observations further 
testing would need to be done. However, it is clear that the addition of growth factors has 
an impact on vessel % area, average vessel length and total vessel length.  
It’s important to note that specific growth factor combinations have different 
biological effects on developing vasculature. Vessel development is complex, and many 
factors contribute to the structure of a microvasculature network. Different organ systems 
also have their own unique vascular topology for organ-specific functions (Kur et al., 
2016). A vascular network with a higher vessel density will have increased oxygen and 
nutrient deliver to its tissues. For example, cardiac tissue has much higher metabolic 
needs compared to adipose tissue and therefore will have a much denser vascular 
network. The overall functionality of a microvasculature network depends on its structure 
and topology.  A sufficient supply of oxygen and nutrients results from an adequate 
amount of branching and spatial distribution of vessels throughout the tissue. (Kopylova 
et al., 2017). Depending on the application different attributes of vasculature might be 
desired. For example, if the goal is to fully perfuse a tissue graft with a microvasculature 
network, vessel percent area would be a very important metric to measure. Depending on 
the application of the vasculature, certain features of the vessels will be desired and 
specific combinations of growth factors can be used to achieve those topologies. There is 
no cumulative, best growth factor combination to achieve the most ideal vasculature.  
Different growth factors need to be strictly refined and managed for a specific 
application.  
A large amount of variability was present between each individual experiment. 
Besides cells being dynamic and extremely sensitive to their culture conditions inside a 
microfluidic device, there does not appear to be a concrete explanation for the variability. 
However, factors like cell confluency, cell passage number and small differences in fibrin 
gels could have impacted the response of the endothelial cells. Further testing to generate 
a large data set would be beneficial to uncover more clear trends in how different 
combinations of growth factors impact the vessel formation. With the limited amount of 
data collected in this work, it is difficult to form concrete conclusions on the growth 
factor combination that produces the most robust microvasculature network. This 
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platform can be used for a wide variety of experimentation. For example, this model may 
be useful to demonstrate cancer cell extravasation. Results from the growth factor 
experiments were expected to influence the protocol for induced vasculogenesis in the 
model. Using the growth factor combination that would be expected yield the desired 
metric of the vessels, with vasculature that has fully developed into a fully perfusable 
network, cancer cells can be injected through the inlet ports and released into the 
vasculature.  This experiment could allow for the observation of cancer cell extravasation 
into the ECM. This platform can also be used to simulate cancer metastasis from the 
primary site to the secondary site using the engineered vasculature  
In tissue engineering engineered grafts often face complications such as poor 
nutrient and oxygen perfusion. This can greatly decrease their viability post 
transplantation. There exists a huge need to develop more reliable methods to vascularize 
tissue grafts. By fully understanding the conditions needed for the development of fully 
perfusable microvasculature network, a more viable method for creating vasculature can 
be created.  A fully working model of vasculature can also aide in other applications such 
as drug development and screening. The more physiologically relevant a 
microvasculature network is, the more we can rely on these models to predict drug 
efficacy and potential side effects. Lastly, many disease states within the body are 
systemic and rely significantly on the vascular system. It is important then to incorporate 
this into any working model of a disease state to get the most accurate results as possible.  
 
Chapter 6  
Conclusions and Future Directions 
The primary goal of this project was to create a functional model of 
vasculogenesis to further understand the ideal conditions needed to develop functional 
vasculature. Specific conditions are needed for optimal vessel development such as the 
composition of the ECM. In this model a fibrin ECM with a density of 9mg/ml was to 
foster the most developed microvasculature networks. Cell specific factors such as initial 
seeding density play a key part as well with a higher density of cells, specifically 14 
million cells/mL in this case, leading to better network formation. Fluid flow across the 
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developing vessels was an important component of the platform as well. In the 
microfluidic model developed here fluid flow control allowed for an increase in vessel 
network formation. Finally, specific combinations of growth factors can have varying 
effects on vessel percent area, vessel length and overall development and stability of the 
network. Across the three metrics measured here, the growth factor combination VEGF + 
PMA resulted in the most developed vasculature.  
 Several modifications could be made to the device to make it more biologically 
relevant and therefore impact the growth and development of the endothelial cells. One 
modification is the incorporation of the secondary resistor to increase the fluid flow over 
the developing vasculature. Constant fluid flow would more closely recapitulate in vivo 
conditions. The design of the microfluidic device presented here was limited in its 
capacity for vasculogenic studies involving EPCs. In future work, this device could be 
modeled to incorporate a microenvironment containing bone marrow. Here the 
recruitment of EPCs to the site of vessel repair could be shown in detail.  
There remains a large space for further development for vasculogenic assays 
specifically in microfluidic device applications. With a thorough understanding of the 
mechanisms behind vasculogenesis and the conditions in which it occurs most 
successfully, advances in modeling cancer metastasis and vascularizing tissue engineered 
grafts can be made. Areas such as tissue engineering, drug development and screening 
and disease models that highlight the dysfunctional occurrences of vasculature can all 
benefit from a fully perfusable, physiologically relevant, microvascular network platform. 
Specifically, this platform can be used in the Wood Lab where a physiologically relevant, 
fully perfusable microvasculature in needed. This is significant as a working model of 
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